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Summary 
While beta-amyloid (Αβ), anxiety and depression have been linked cross-sectionally to reduced 
memory function in healthy, non-demented older adults, prospective data evaluating these 
associations are lacking. Using data from an observational cohort study of 178 healthy, non-
demented older adults followed for three years, we found that anxiety symptoms significantly 
moderated the relation between Αβ level and decline in verbal (Cohen’s d=.65) and episodic 
(Cohen’s d=.38) memory. Anxiety symptoms were additionally linked to greater decline in 
executive function, irrespective of Αβ and other risk factors. These findings suggest that 
interventions to mitigate anxiety symptoms may help delay memory decline in otherwise healthy 
older adults with elevated Αβ. 
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Introduction 
Beta-amyloid (Αβ) accumulates incrementally with age and is abnormally elevated in the 
majority of individuals who meet criteria for mild cognitive impairment (MCI) and Alzheimer’s 
disease (AD)1. Abnormal levels of Αβ are also observed in approximately 30% of healthy, non-
demented older adults2 and are associated with clinically significant decline in episodic memory 
over 18-36 months.3 Anxiety and depression are also linked to increased Αβ in healthy, non-
demented older adults, as well as in adults with MCI and AD,4,5 and are known to deleteriously 
affect episodic memory and related cognitive functions, such as attention and executive 
function.6,7 Taken together, these observations suggest that anxiety and depression may 
contribute to Αβ-related decline in episodic memory and related cognitive domains in otherwise 
healthy older adults. However, prospective data evaluating this possibility are lacking. Given 
that anxiety and depression are amenable to treatment, their identification as determinants or 
moderators of Αβ-related cognitive decline in healthy older persons is important for managing 
preclinical and prodromal phases of AD prior to the availability of anti-amyloid therapies. 
 
In this study, we evaluated whether elevated anxiety and depressive symptoms moderated the 
effect of elevated Αβ on cognitive decline in one of the largest cohorts of healthy, non-demented 
older adults who have undergone assessment with 11C-Pittsburgh Compound B (PiB) and 
whose clinical status was followed prospectively over three years. We hypothesized that 
elevated anxiety and depressive symptoms at baseline would be associated with increased 
memory decline over the three-year period of assessment, and that this effect would be 
independent of traditional risk factors for cognitive decline (e.g., age, education, IQ, and 
apolipoprotein E [APOE] genotype). 
 
Method 
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Sample. A total of 178 older adults who completed PiB imaging as part of the Australian 
Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing2 participated in this study. 
Participants were recruited from among the healthy, non-demented older adult group enrolled in 
the AIBL study (i.e., 25% of the group who completed PiB imaging). Exclusion criteria included: 
schizophrenia; depression (15-item Geriatric Depression Score ≥ 6); Parkinson’s disease; 
cancer (except basal cell skin carcinoma) within the last two years; symptomatic stroke; 
uncontrolled diabetes; current regular alcohol use exceeding two standard drinks per day for 
women or four per day for men. For each assessment, a clinical review panel considered all 
available medical, psychiatric, and neuropsychological information to confirm the cognitive 
health of each participant. Selection of healthy older adults into the full AIBL cohort was 
controlled to ensure: (a) a wide age distribution from 60 years through to the very elderly, and 
(b) that approximately 50% had subjective memory complaint; for the 25% of this cohort who 
completed PiB imaging, an additional criterion was added to enrich the sample with APOE ε4 
carriers: (c) that approximately 50% of the sample were APOE ε4 carriers. The study was 
approved by and complied with the regulations of the institutional research and ethics 
committees of Austin Health, St. Vincent’s Health, Hollywood Private Hospital, and Edith Cowan 
University.  All participants provided written informed consent prior to participating in the study.   
 
PET Imaging and APOE genotyping.  Aβ imaging with PET was conducted using 11C-Pittsburgh 
Compound B (PiB). Imaging was conducted over a 30-minute acquisition period that was 
started 40-70 minutes after the injection of PiB.  PET standardized uptake value (SUV) data 
were summed and normalized to the cerebellar cortex SUV, yielding a region-to-cerebellar ratio 
termed SUV ratio (SUVR). PiB SUVR levels reflect the mean of Αβ in frontal, post-cingulate, 
lateral temporal, and occipital cortices. In line with previous studies, SUVR was classified 
dichotomously as either negative or positive on the basis of SUVR < or ≥ 1.5.  An 80ml blood 
sample was also obtained from each participant, 0.5ml of which was sent to a clinical pathology 
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laboratory for APOE genotyping. 
 
Anxiety and depressive symptoms.  Anxiety and depressive symptoms were assessed at the 
baseline visit using the Hospital Anxiety and Depression Scale (HADS). A total score ≥ 8 on the 
anxiety and depression items are indicative of clinically elevated anxiety and depressive 
symptoms, respectively.8 
 
Neuropsychological assessment.  Comprehensive neuropsychological evaluations were 
conducted at baseline, and at 18- and 36-month follow-ups.  Composite indices of episodic 
memory, verbal memory, visual memory, executive function, language, attention, and 
visuospatial function were derived based on theory and clinical consensus.9 The Episodic 
Memory composite score was comprised of scores on the California Verbal Learning Test, 
Second Edition (CVLT-II) delayed recall and Rey Complex Figure Test (RCFT) 30 minute 
delayed recall tests. The Verbal Memory composite score was comprised of scores on Logical 
Memory delayed recall, CVLT-II delayed recall, and CVLT-II d’ measures. The Visual Memory 
composite score was comprised of scores on the RCFT 3-minute delayed recall, RCFT 30-
minute delayed recall, and RCFT recognition tests. The Executive Function composite score 
was comprised of scores on the Stroop Colors/Dots, Letter Fluency (FAS), and Category 
Switching (Fruit/Furniture) tests. The Language composite score was comprised of scores on 
the Category Fluency (Animals/Boys’ Names) and Boston Naming tests. The Attention 
composite score was comprised of scores on the Digit Span, Stroop Dots, and Digit Symbol 
Coding tests. The Visuospatial composite score was comprised of scores on the RCFT Copy 
and Clock Drawing tests. Factor analyses revealed strong loadings (i.e., all factor loadings 
≥ .47) of each of the component measures on these composite scores.  
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Subjective memory complaint. Subjective memory impairment was assessed dichotomously (i.e., 
“No” or “Yes”) using the question: “Do you have difficulties with your memory?” 
 
Data analysis.  Descriptive statistics were generated to summarize sample characteristics.  To 
evaluate the relation between baseline anxiety and depression, other risk factors, and change in 
cognitive functioning over the 3-year study period, we conducted a series of linear mixed-effects 
models using maximum likelihood estimation and an unstructured covariance matrix. Baseline 
anxiety symptoms (i.e., score ≥ 8 on anxiety items of the HADS), depressive symptoms (i.e., 
score ≥ 8 on depression items of the HADS), and PiB screening status (standardized uptake 
value ratio [SUVR] < vs. ≥ 1.5 [PiB- vs. PiB+]),3 APOE genotype (ε4 carrier vs. non-ε4 carrier), 
age, education, IQ, and subjective memory complaint were entered as fixed factors; participant 
as a random factor; and composite cognitive test scores as dependent variables in separate 
analyses.  Cohen’s d values were computed to estimate effect sizes of group differences. 
 
Results 
 
Of the 178 healthy, non-demented older adults who completed a baseline assessment, 163 
(91.6%) completed an 18-month follow-up and 138 (77.5%) completed a 36-month follow-up. 
Table 1 shows demographic and clinical characteristics of the sample. PiB+ status was 
associated with greater decline in episodic, verbal, and visual memory over the 3-year study 
period (Table 1). Anxiety symptoms moderated the relation between PiB status and decline in 
episodic (Cohen’s d=.38) and verbal (Cohen’s d=.65) memory, such that PiB+ older adults with 
elevated anxiety symptoms showed significantly greater decline relative to PiB+ older adults 
without elevated anxiety symptoms; baseline anxiety symptoms were also associated with lower 
overall attention and executive function scores, and greater decline in executive function over 
time, irrespective of PIB status. The main effect of elevated depressive symptoms and 
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interactions of elevated depressive symptoms by time, PiB status, and time x PiB status were 
not significant for any of the cognitive measures.  Depressive symptoms were significantly 
associated with subjective memory complaints (87.5% of the depressive symptoms group vs. 
51.8% of the no depressive symptoms group reported subjective memory complaints, 
[Χ2(1)=3.91, p=.048]), but anxiety symptoms were not (52.2% of the anxiety symptoms group vs. 
53.9% of the no anxiety symptoms group reported subjective memory complaints, [Χ2(1)=0.02, 
p=.88]). 
 
Discussion 
 
Consistent with prior work,3 results of this study revealed that abnormal levels of Αβ were 
associated with decline in episodic, verbal, and visual memory in healthy, non-demented older 
adults.  They extend this work by demonstrating that anxiety, but not depressive, symptoms 
moderated the effect of high Αβ burden on decline in episodic and verbal memory. Specifically, 
among individuals with abnormal Αβ, those with elevated anxiety symptoms showed a 
significantly greater decline in episodic and verbal memory over a 3-year study period than 
those without elevated anxiety symptoms. This additional deleterious effect of anxiety symptoms 
was, by convention, moderate in magnitude even after statistical adjustment for well-known 
determinants of cognitive decline, including age, education, IQ, APOE genotype, depressive 
symptoms, and subjective memory complaints. Anxiety symptoms were unrelated to subjective 
memory complaints at baseline, which suggests that these symptoms were more general in 
nature and likely reflective of generalized anxiety symptoms, such as worry, fearfulness, and 
restlessness.8  Notably, results of this study did not support our hypothesis, based on extant 
literature, that anxiety and depressive symptoms at baseline would be associated with 
increased memory decline over the 3-year study period. Instead, anxiety symptoms predicted 
overall attention and executive function, and decline in executive function in the full sample; and 
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moderated the association between high Αβ burden and memory decline among healthy, non-
demented older adults with elevated Αβ.  The low prevalence of depressive symptoms (4.5%) 
may, at least in part, account for the lack of association between these symptoms and cognitive 
change; additional research with more clinically diverse samples will be useful in evaluating the 
direct and moderating effect of depressive symptoms on cognitive change in preclinical AD. 
 
That anxiety symptoms moderated the relation between Αβ level and decline in episodic and 
verbal memory suggests that this interaction occurs at the level of the hippocampus.  Elevated 
anxiety symptoms may moderate the effect of Αβ on these aspects of memory by increasing 
endogenous levels of glucocorticoids, which consequently damage the hippocampus and result 
in more pronounced memory decline over time.10 Anxiety also diverts and preoccupies 
prefrontally-mediated attentional resources to fear- and threat-related information, which may in 
turn negatively affect encoding and retention of verbal information, as well as other prefrontally-
mediated cognitive processes such as attention and executive function.7,10   
 
While this study is limited by the relatively lower proportion of older adults who screened 
positive for depressive symptoms relative to anxiety symptoms, these results nevertheless 
suggest that mitigation of elevated anxiety symptoms may help delay episodic and verbal 
memory decline in healthy, non-demented older adults with elevated Αβ. Of note, because the 
prevalence of ε4 carriers in the AIBL sample of healthy older adults who underwent 
neuroimaging was, by design, high (40.7%), additional research in population-based samples of 
healthy older adults is needed to evaluate the generalizability of these results. Further research 
is also needed to elucidate neurobiological mechanisms that mediate the relation between Αβ, 
anxiety symptoms, and cognitive decline; and evaluate the effect of treating elevated anxiety 
symptoms in mitigating memory decline in normal aging and preclinical AD.  
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Table 1.  Sample characteristics and results of linear mixed-effects models examining the relation between cerebral Αβ, anxiety and depressive symptoms, 
and cognitive outcomes over a 3-year period in healthy older adults 
 
Sample characteristics      
 M (SD) or  
N (%) 
     
Age 71.5 (7.4)      
Female sex 89 (50.0%)      
Education       
    <=12 years 83 (46.6%)      
    13+ years 95 (53.4%)      
WTAR IQ 111.7 (6.7)      
MMSE 28.7 (1.2)      
PiB SUVR > 1.5  55 (30.9%)      
APOE ε4 carrier 72 (40.7%)      
HADS anxiety score 4.1 (2.8)      
Positive screen for anxiety 23 (12.9%)      
HADS depression score 2.8 (2.3)      
Positive screen for depression 8 (4.5%)      
Subjective memory complaint 95 (53.7%)      
        
Results of linear mixed-effect model analyses     
 Episodic Memory Verbal Memory Visual Memory Attention Language Visuospatial Executive 
 F p F p F p F p F p F p F p 
PiB SUVR > 1.5 1.74 .19 5.45 .020 1.72 .19 .01 .94 .08 .77 .01 .94 .02 .90 
Anxiety symptoms .01 .99 2.08 .15 .15 .70 4.96 .026 .01 .98 .29 .59 3.95 .047 
Depressive symptoms .07 .79 .01 .93 .31 .58 .07 .79 3.74 .06 .31 .58 1.02 .31 
Time 12.85 <.001 20.67 <.001 .32 .57 3.95 .048 4.64 .032 30.42 <.001 5.82 .016 
PiB x Anxiety symptoms 1.69 .19 4.98 .026 1.75 .19 1.78 .18 .01 .95 .98 .32 .20 .65 
PiB x Depressive symptoms 2.63 .11 .20 .66 3.43 .07 1.72 .19 3.07 .08 .27 .60 .56 .46 
PiB x Time 15.15 <.001 20.54 <.001 4.60 .033 .01 .91 .87 .35 .46 .50 .01 .91 
Anxiety symptoms x Time 1.82 .18 2.20 .14 .11 .74 2.04 .15 .01 .99 .56 .45 4.41 .037 
Depressive symptoms x Time .19 .66 .01 .94 .01 .99 .34 .56 .42 .51 .05 .83 .01 .97 
PiB x Time x Anxiety symptoms 4.20 .041 3.97 .047 1.26 .26 1.74 .19 .06 .81 .97 .33 1.17 .28 
PiB x Time x Depressive symptoms 1.26 .26 .28 .59 1.14 .29 .15 .70 2.22 .14 .17 .68 .01 ,94 
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Note. PiB level reflects mean of Αβ in frontal, post-cingulate, lateral temporal, and occipital cortices. Linear mixed-effects models are adjusted 
for age, education, IQ, APOE genotype, and subjective memory complaint.   
WTAR=Wechsler Test of Adult Reading; MMSE=Mini-Mental State Examination; PiB SUVR=Pittsburgh Compound B Standardized Uptake 
Value Ratio; HADS=Hospital Anxiety and Depression Scale.  SE=standard error. 
 
               
Adjusted slope estimates by PiB and Anxiety group           
 PiB-/Anxiety- PiB-/Anxiety+ PiB+/Anxiety- PiB+/Anxiety+  Pairwise comparisons   
 Mean (SE) Mean (SE) Mean (SE) Mean (SE)     
       Episodic memory .14 (.09) .26 (.25) -.29 (.14) -.65 (.35)  3,4<1; 4<3   
       Verbal memory .18 (.09) .21 (.25) -.32 (.14) -.93 (.34)  3,4<1; 4<3   
